Regeneron Pharmaceuticals, Inc. (REGN)

Pharmaceutical Preparations

Latest Price

$758.27

TTM P/E

18.78

Normalized P/E

18.82

Div Yield

0.36%

Book Value

308.48

P/B Ratio

2.46

Valuation metrics

EPS: $41.48

Book value / share: $287.82

Formula: √(22.5 × EPS × BVPS)

Graham Number

$518.29

32% downside

Norm. op. income: $4.0B (median of 7yr)

Tax rate: 11%

Discount rate: 10%

Growth assumption: zero (EPV is a no-growth value)

Earnings Power Value

$389.06

49% downside

Base FCF: $4.1B (median of recent 5yr)

Growth: -3%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$428.04

44% downside

EPS: $41.48

Target P/E: 19×

Formula: EPS × P/E

P/E Fair Value

$788.12

+4% upside

89.8% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
BlackRock, Inc.	9.11M	$5.68B	8.87%	+165.8K	2026-06-30
Vanguard Capital Management LLC	6.63M	$4.13B	6.45%	-25.2K	2026-06-30
Dodge & Cox	4.87M	$3.04B	4.74%	+412.9K	2026-06-30
State Street Corp	4.83M	$3.01B	4.70%	+170.2K	2026-06-30
Invesco Ltd.	3.94M	$2.46B	3.83%	+2.22M	2026-06-30
JPMorgan Chase & Co	3.77M	$2.38B	3.67%	-166.0K	2026-06-30
Vanguard Portfolio Management LLC	3.18M	$1.98B	3.09%	+1.45M	2026-06-30
Franklin Resources Inc	2.77M	$1.73B	2.70%	+49.8K	2026-06-30
Geode Capital Management, LLC	2.63M	$1.63B	2.55%	+18.1K	2026-06-30
Nuveen, LLC	2.02M	$1.26B	1.96%	-45.1K	2026-06-30